Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is 18 years of age or older at screening.~2. Patient has a documented and confirmed CF diagnosis.~3. Patient has performed an OGTT for diagnosis of INDENT, IGT and de novo CFRD within 12 months prior to screening visit.~4. Patient has a Body Mass Index (BMI) of at least 17 kg/m2.~5. Patient has signed written informed consent.~6. Patient is able and willing to self-monitor blood glucose level at home.~7. Female patients of childbearing potential must have a negative pregnancy test (serum or urine) and agree to use adequate birth control from screening throughout the study and for the 30 days after the last study drug administration.~8. If a male patient has not been vasectomized at least 6 months before screening and partners with a woman of childbearing potential, he must be willing to use an acceptable contraceptive method throughout the study and for the 30 days after the last study drug administration.~Exclusion Criteria:~1. Patient has recent or ongoing infection requiring intravenous treatment with an anti-infective agent within 30 days before screening.~2. Patient is concurrently taking high dose of ibuprofen (\>30 mg/kg) or is using corticosteroids (except inhaled and topical corticosteroids).~3. Patient is currently using weight-loss medications.~4. 4. Patient has used any moderate/potent inhibitor of cytochrome P450 (CYP) 2C9 isozyme or strong inhibitor of CYP3A isozyme within 30 days prior to the first study drug administration.~5. Patient has significantly elevated liver enzyme levels, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 Upper Limit of Normal (ULN) or total bilirubin above ULN at screening.~6. Patient has a history of chronic alcohol or other substance abuse as determined at screening that may prevent study compliance based on Investigator judgment.~7. History of malignancy of any organ system, treated or untreated, within the past 5 years other than basal or squamous cell skin cancer.~8. Patient has unstable chronic heart failure that has required change in therapy within 2 months prior to screening.~9. Patient with known non-controlled history of infection with Human Immunodeficiency Virus (HIV) and/or active Hepatitis.~10. Woman who is pregnant, breast-feeding or planning a pregnancy during the course of the study.~11. Woman of childbearing potential who is unwilling to use adequate birth control throughout the duration of the study.~12. Patient has any condition that, in the Investigator's opinion, is likely to interfere with study conduct and compliance.~13. Patient has participated in an investigational clinical trial within 30 days (or 5 half-lives, whichever is longer) prior to screening visit.~14. Patient is under insulin and/or repaglinide treatment at screening/baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PBI4050 (Type: EXPERIMENTAL): Four 200 mg capsules (total 800 mg) administered orally, once daily.
- Placebo (Type: PLACEBO_COMPARATOR): Four 200 mg capsules (total 800 mg) administered orally, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).